AAMU
TBPH icon

Amundi Asset Management US’s Theravance Biopharma TBPH Stock Holding History

Amundi Asset Management US’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-47,182
Closed -$698K – 1585
2020
Q3 		$698K Buy
+47,182
New +$884K ﹤0.01% 1219
2019
Q3 		– Sell
-4,600
Closed -$75K – 1700
2019
Q2 		$75K Hold
4,600
– – ﹤0.01% 1589
2019
Q1 		$104K Sell
4,600
-900
-16% -$22.8K ﹤0.01% 1551
2018
Q4 		$141 Buy
5,500
+1,400
+34% +$37.8K ﹤0.01% 1449
2018
Q3 		$134K Buy
+4,100
New +$112K ﹤0.01% 1496
2018
Q1 		– Sell
-1,500
Closed -$42K – 1594
2017
Q4 		$42K Buy
+1,500
New +$44.4K ﹤0.01% 1510

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Asset Management US's TBPH Position: Q4 2020 in Review

Amundi Asset Management US sold out of Theravance Biopharma (TBPH) in Q4 2020, closing a stake of 47,182 shares — an estimated $698K sold.

Amundi Asset Management US first reported a position in TBPH in Q4 2017 and held it in 6 quarters. The position peaked at $698K in Q3 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

  • Amundi Asset Management US reported no remaining Theravance Biopharma position as of Q4 2020 after selling out during the quarter.
  • Amundi Asset Management US sold 47,182 Theravance Biopharma shares in Q4 2020, an estimated $698K.
  • Amundi Asset Management US first reported a position in Theravance Biopharma in Q4 2017 and held it in 6 quarters.
  • Amundi Asset Management US's Theravance Biopharma position peaked at $698K in Q3 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on Amundi Asset Management US's 13F filing for Q4 2020, filed 16 Feb 2021.